NIH Clinical Center Senior Staff
Henry Masur, MD
Henry Masur earned his undergraduate degree from Dartmouth College and his medical degree from Cornell University Medical College. He completed his internship and residency in internal medicine at New York Hospital and Johns Hopkins Hospital. Following a fellowship at Cornell in the Division of Infectious Diseases and Internal Medicine, he served as an Instructor and Assistant Professor of Medicine in the Infectious Diseases Division at Cornell from 1978 to 1982.
Dr. Masur was recruited to NIH to jointly found a new department of critical care medicine and an HIV/AIDS program with NIAID. He became Chief of the Critical Care Medicine Department in 1989. During the past 20 years the department has attained national and international acclaim for its leadership in areas of sepsis, emerging infections, HIV/AIDS, lung biology and sickle cell disease. The department has developed a highly competitive, highly sought training program in critical care medicine which permits candidates to train in pulmonary medicine, infectious diseases, or cardiology as a second subspecialty. The department also has expanded its clinical services and serves as a pivotal component of the NIH Clinical Center which cares for patients with complex medical disorders.
Dr. Masur is well known for his expertise in HIV-related opportunistic infections. His department has published many pivotal studies related in particular to pneumocystis pneumonia. He is the co-editor of the NIH-CDC-IDSA Guidelines for Management of Opportunistic Infections in Adults and Adolescents with HIV Infections, Co-Editor of the textbook AIDS Therapy, and is Past President, Infectious Diseases Society of America. He is also well known in the field of critical care related to infectious diseases, and is the co-chair of IDSA-SCCM Guidelines on Prevention of Intravenous Catheter infections and Evaluation of Fever in the ICU.
Dr. Masur leads the District of Columbia Partnership for AIDS Progress, a unique collaboration between NIH and the DC government which aims to create an urban model for decreasing the impact of HIV/AIDS on underserved populations. The program is focusing on HCV-HIV co-infection, mental health issues, and improving access and adherence to appropriate therapies.
Dr. Masur is Clinical Professor of Medicine at George Washington University and holds appointments at the University of Maryland and the Washington Hospital Center as well.
Selected Honors and Awards
John Phillips Award, American College of Physicians, 2010; Feder lectureship, Weill Cornell Medical College, 2008; Infectious Diseases Society of America, 2002-2008; (Council 2001-2004, Vice President 2004-2005, President Elect 2005-2006, President 2006-2007, Past President 2007-2008); Zucker Family Lectureship, Weill College of Medicine, Cornell University; 2003; Astute Clinician Lecture, National Institutes of Health, 2002; Kirby Lectureship, University of Washington, 2002; Taubin Memorial Lectureship, Children's National Medical Center, 2002; International Association of Physicians in AIDS Care Hero Award (41 named internationally), 2000;
American Society for Clinical Investigation
Association of American Physicians
Kattakuzhy S, Gross C, Emmanuel B, Teferi G, Jenkins V, Silk R, Akoth E, Thomas A, Ahmed C, Espinosa M, Price A, Rosenthal E, Tang L, Wilson E, Bentzen S, Masur H, Kottilil S; and the ASCEND Providers. Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial. Ann Intern Med. 2017;167:311-318.
Chertow DS, Palmore TN, Masur H. Critical Care Medicine After the 2014-2015 Ebola Outbreak: Are We Ready If It Happens Again? Crit Care Med. 2016 Mar;44(3):457-9.
Meissner EG, Kohli A, Virtaneva K, Sturdevant D, Martens C, Porcella SF, McHutchison JG, Masur H, Kottilil S. Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis. J Viral Hepat. 2016 Jul;23(7):496-505.
Townsend K, Petersen T, Gordon LA, Kohli A, Nelson A, Seamon C, Gross C, Tang L, Osinusi A, Polis MA, Masur H, Kottilil S. Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir. AIDS. 2016 Jan;30(2):261-6.
Kohli A, Kattakuzhy S, Sidharthan S, Nelson A, McLaughlin M, Seamon C, Wilson E, Meissner EG, Sims Z, Silk R, Gross C, Akoth E, Tang L, Price A, Jolley TA, Emmanuel B, Proschan M, Teferi G, Chavez J, Abbott S, Osinusi A, Mo H, Polis MA, Masur H, Kottilil S. Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial. Ann Intern Med. 2015 Dec 15;163(12):899-907.
Wilson EM, Kattakuzhy S, Sidharthan S, Sims Z, Tang L, McLaughlin M, Price A, Nelson A, Silk R, Gross C, Akoth E, Mo H, Subramanian GM, Pang PS, McHutchison JG, Osinusi A, Masur H, Kohli A, Kottilil S. Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens. Clin Infect Dis. 2016 Feb 1;62(3):280-288.
Meissner EG, Decalf J, Casrouge A, Masur H, Kottilil S, Albert ML, Duffy D. Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy. PLoS One. 2015 Jul 16;10(7):e0133236. doi: 10.1371/journal.pone.0133236. eCollection 2015. Erratum in: PLoS One. 2015;10(9):e0139818.
Kottilil S, Wright M, Polis MA, Masur H. Treatment of hepatitis C virus infection. Ann Intern Med. 2015 Mar 17;162(6):459.
Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG, Bon D, Silk R, Gross C, Price A, Sajadi M, Sidharthan S, Sims Z, Herrmann E, Hogan J, Teferi G, Talwani R, Proschan M, Jenkins V, Kleiner DE, Wood BJ, Subramanian GM, Pang PS, McHutchison JG, Polis MA, Fauci AS, Masur H, Kottilil S. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015 Mar 24-31;313(12):1232-9.
Kohli A, Osinusi A, Sims Z, Nelson A, Meissner EG, Barrett LL, Bon D, Marti MM, Silk R, Kotb C, Gross C, Jolley TA, Sidharthan S, Petersen T, Townsend K, Egerson D, Kapoor R, Spurlin E, Sneller M, Proschan M, Herrmann E, Kwan R, Teferi G, Talwani R, Diaz G, Kleiner DE, Wood BJ, Chavez J, Abbott S, Symonds WT, Subramanian GM, Pang PS, McHutchison J, Polis MA, Fauci AS, Masur H, Kottilil S. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet. 2015 Mar 21;385(9973):1107-13.
NOTE: PDF documents require the free Adobe Reader.
This page last updated on 12/13/2017